$ネクター セラピューティクス(NKTR.US)$Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
$ネクター セラピューティクス(NKTR.US)$• Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata. • The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025. • Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
Nektar Therapeutics' CEO, Howard Robin, is pleased with the deal, stating it strengthens the company's finances and extends its cash runway to Q3 2026. He also emphasized the potential of rezpegaldesleukin, a novel biologic in Phase 2b studies.
$ネクター セラピューティクス(NKTR.US)$Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255 MT Newswires· 1 min ago Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells. "Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
wooperスレ主Wind_Storm:
Alert Mode ON, The Pulse is Racing! Time to roll up those sleeves and dive into today's picks. Yesterday's highlight: a notable 32.63% short move. Here are today's signals: SFT Long > 0.2135 Short < 0.2015 TGL Long > 0.5605 Short < 0.4695 RVLP Long > 0.0822 Short < 0.0695 MCOM Long > 0.0500 Short < 0.0455 ARDX Long > 4.16 Short < 3.79 Let’s seize the day and stay vigilant!
$ネクター セラピューティクス(NKTR.US)$Nektar Presents New Responder Data For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy, In Late-Breaking News Oral Presentation At 2023 EADV Congress Benzinga· 1 min ago – Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period – – New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQ...
ネクター セラピューティクスに関するコメント
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
Benzinga· 1 min ago
– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –
– New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQ...
まだコメントはありません